BioSpace News Archive

Olema Pharmaceuticals, Inc. announced results from a Phase 2 clinical study of palazestrant, the Company’s complete estrogen receptor antagonist and selective ER degrader, for the treatment of metastatic ER+/HER2- breast cancer.

Sutro Biopharma, Inc. announced initial results from a Phase 1 dose-expansion study of luveltamab tazevibulin, a novel Folate receptor alpha -targeting ADC, in patients with endometrial cancer, in a mini oral presentation at the 2023 European Society For Medical Oncology Congress in Madrid, Spain.

Updated results from the BEGONIA Phase Ib/II trial for the cohort of patients treated with datopotamab deruxtecan plus IMFINZI® showed that the combination demonstrated durable tumor responses and no new safety signals in patients with previously untreated advanced or metastatic triple-negative breast cancer with six months additional follow-up from the previous data cut-off.

Natera, Inc. announced updated data from the GALAXY arm of the CIRCULATE-Japan trial further showcasing the ability of the Signatera™ molecular residual disease test to help identify patients with resectable colorectal cancer who are at an increased risk of recurrence and predict who are most likely to benefit from adjuvant chemotherapy.

Regeneron Pharmaceuticals, Inc. and Sanofi announced that positive results from a Phase 3 trial evaluating the investigational use of Dupixent® showed consistent efficacy and safety for up to one year in children aged 1 to 11 years with eosinophilic esophagitis.

Exact Sciences Corp. announced late-breaking data from the pivotal BLUE-C trial showing the next-generation Cologuard® test met all study endpoints, demonstrating 94 percent sensitivity for colorectal cancer at 91% specificity, during the American College of Gastroenterology Annual Meeting 2023.

Adiso Therapeutics, Inc. announced positive topline data from its Phase 1b multiple ascending dose clinical trial evaluating ADS051 in patients with moderate-to-severe ulcerative colitis.

InxMed Co., Ltd announces that clinical data of Ifebemtinib, a highly potent and selective oral inhibitor of focal adhesion kinase, in platinum-resistant recurrent ovarian cancer and triple-negative breast cancer has been presented at the 2023 European Society for Medical Oncology Congress taking place October 20-24 in Madrid, Spain.

Positive results from a Phase 3 trial demonstrated the efficacy and safety profile of Dupixent® for up to one year in children aged 1 to 11 years with eosinophilic esophagitis was consistent.

Celltrion USA announced that the U.S. Food and Drug Administration has approved ZYMFENTRA® for maintenance therapy in adults with moderately to severely active ulcerative colitis and Crohn’s disease following treatment with an infliximab product administered intravenously.